Core Insights - Shift4's founder Jared Isaacman has been appointed as the 15th Administrator of NASA, marking a significant leadership transition for the company [1] - Following Isaacman's confirmation, he resigned from his position as Executive Chairman of Shift4's Board of Directors [1] - CEO Taylor Lauber has been appointed as the new Chairman of the Board of Directors [1]

Core Insights - Laird Superfood has expanded its Hydrate product line with two new flavors: Wild Berry and Tropical Punch, both containing zero added sugar and real-food ingredients [1][2] - The Hydrate powders include Aquamin™, a red marine algae that provides essential minerals, and are lightly sweetened with monk fruit [2][3] - The full Hydrate lineup now consists of five flavors, including Original, and is available in single-serve sticks and a Variety Pack [4] Product Details - The new Wild Berry flavor features antioxidant-rich berries from Patagonia, while Tropical Punch combines various fruits and real orange oil [1][2] - Each Hydrate product contains electrolytes like sodium and potassium to naturally replenish the body [3] - The Original flavor is made from only two ingredients: coconut water and Aquamin [2] Company Background - Laird Superfood was co-founded by Laird Hamilton and Gabby Reece in 2015, focusing on minimally processed superfood products that support active lifestyles [6] - The brand has expanded its offerings from superfood creamers to include instant lattes, coffees, bars, and prebiotic daily greens [6] - The company's mission is to provide simple ingredients that fuel energy, endurance, and overall well-being [6]

Core Viewpoint - Nxera Pharma's GPR52 agonist program for schizophrenia will not be licensed by Boehringer Ingelheim, leading to the reversion of all rights and data back to Nxera [1] Group 1: GPR52 Agonist Program - NXE'149 and other GPR52 agonists were developed using Nxera's NxWave™ structure-based drug design platform to address positive, negative, and cognitive symptoms of schizophrenia [2] - A Phase 1 trial of NXE'149 showed a favorable safety profile with no severe adverse events and demonstrated dose-proportional exposure and a long half-life supporting once-daily dosing [3] - The expression of GPR52 in brain regions linked to various schizophrenia symptoms suggests NXE'149 may treat all three symptom domains, offering a potential new therapeutic option [4] Group 2: Future Plans and Financial Impact - Nxera plans to explore strategic opportunities, including a formal out-licensing process for the GPR52 program in 2026 [5] - The decision by Boehringer Ingelheim does not impact Nxera's consolidated financial results for the current accounting period [5] - CEO Christopher Cargill expressed optimism about the potential of the GPR52 program despite the setback, highlighting the strong scientific and clinical foundations established [6] Group 3: Company Overview - Nxera Pharma is focused on developing specialty medicines to meet unmet medical needs in Japan and globally, leveraging its NxWave™ discovery platform [7][10] - The company has an extensive pipeline of over 30 active programs targeting major unmet needs in areas such as obesity, neurology, and immunology [9] - Nxera employs approximately 400 people across key locations including Tokyo, London, and Basel [10]

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Coupang, Inc. (NYSE: CPNG) between August 6, 2025 and December 16, 2025, both dates inclusive (the "Class Period†). The lawsuit seeks to recover damages for Coupang investors under the federal securities laws. To join the Coupang class action, go to https://rosenlegal.com/submit-form/?case_id=8383 or call Phillip Kim, Esq. toll-. ...

CNBC's Jim Cramer reviewed Thursday's market action, telling investors that gains in consumer-oriented companies are propelling stocks higher despite losses from Big Tech names — whose enormous spending on artificial intelligence is drawing scrutiny."Retail is such a huge portion of this economy, it can mask the questionable kinds of transactions we've been seeing at the highest level of tech," he said.The S&P 500 snapped its four-day losing streak on Thursday, finishing the session up 0.79%. The Nasdaq Com ...

Core Insights - Heico Corporation reported quarterly earnings of $1.33 per share, exceeding the Zacks Consensus Estimate of $1.20 per share, and showing an increase from $0.99 per share a year ago, resulting in an earnings surprise of +10.83% [1] - The company achieved revenues of $1.21 billion for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 4.99%, and up from $1.01 billion in the same quarter last year [2] - Heico has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of Heico's stock will largely depend on management's commentary during the earnings call and the sustainability of the stock's price movement based on recent earnings and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.29 on revenues of $1.15 billion, and for the current fiscal year, it is $5.38 on revenues of $4.88 billion [7] Industry Context - Heico operates within the Aerospace - Defense Equipment industry, which is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Historical data suggests that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1, highlighting the potential for Heico's stock performance in a strong industry context [8]

Core Insights - Scholastic reported revenue of $551.1 million for the quarter ended November 2025, reflecting a 1.2% increase year-over-year, with EPS at $2.57 compared to $1.82 in the same quarter last year, indicating a strong earnings performance despite a slight revenue miss against estimates [1] Revenue Breakdown - International revenues reached $89.5 million, exceeding the average estimate of $89.29 million, marking a year-over-year increase of 3.2% [4] - Entertainment revenues were reported at $15.1 million, falling short of the $16.45 million average estimate [4] - Education Solutions revenues totaled $62.2 million, below the estimated $64.8 million, representing a significant year-over-year decline of 12.6% [4] - Children's Book Publishing and Distribution revenues were $380.9 million, slightly below the estimated $383.12 million, but showing a year-over-year increase of 3.8% [4] Stock Performance - Scholastic's shares have returned 2.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a 0.9% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Viewpoint - ArrowMark Financial Corp. has entered into a securities purchase agreement to sell 673,249 shares of common stock at a price of $22.28 per share, which is slightly above the Net Asset Value of $22.20, indicating a positive impact for current shareholders [1]. Group 1: Offering Details - The registered direct offering is expected to generate proceeds of approximately $14.99 million, excluding legal and administrative expenses [2]. - The offering is conducted under a "shelf" registration statement filed with the SEC, allowing for the sale of securities through a prospectus [3]. Group 2: Company Overview - ArrowMark Financial Corp. is a non-diversified, closed-end fund listed on NASDAQ under the symbol "BANX," with an investment objective focused on providing current income primarily through investments in regulatory capital securities of financial institutions [5].

As we move into the final days of 2025, we have had another banner year for local stocks, with the Straits Times Index (SGX: ^STI) up roughly 20.8% year-to-date (YTD). With optimism surrounding earnings and the historical trend of window dressing, where funds look to add stocks that have done well for the year to show investors, they have made the right picks. Hence, we might be due for a year-end rally in stocks. Let’s shine the spotlight on three Singapore blue chips that could benefit. DFI Retail Group H ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .If it looks like a duck, swims like a duck, and quacks like a duck, then it probably is a duck.Leo Nelissen is an analyst focusing on major economic developments related to supply chains, infrastructure, and commodities. He is a contributing author for iREIT®+HOYA Capital.As a m ...